Neuland Laboratories share news, announcements and annual reports
NSE: NEULANDLABBSE: 524558Pharmaceuticals & BiotechnologySmall Cap
Neuland Laboratories Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 1994 on BSE, Oct 2008 on NSE
Last close ₹19,280.00down ₹690.00 (3.46%)BSE ₹19,275.95
Share price at the NSE close on 29 Oct 2026. Previous close ₹19,970.00.
29 Oct: open ₹19,995.00, high ₹20,015.00, low ₹19,130.00
52-week range of traded prices to 29 Oct 2026
₹11,500.00Low, 23 Mar 2026₹24,225.00High, 9 Sep 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹24,736 Cr356th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 49.69
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 13.20
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.18%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 29.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 32.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.10
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 71,65457.6% delivered
Neuland Laboratories share news and announcements
837 announcements, routine notices left out, newest first. Page 13 of 17.
Nov 2016
4 Nov · Board meeting
4 Nov · Results
2 Nov · Business
1 Nov · Updates
Oct 2016
20 Oct · Limited Review Report
Sep 2016
2 Sep · Statement on Impact of Audit Qualifications
Aug 2016
29 Aug · Legal
Exchange has sought clarification from Neuland Laboratories Limited with respect to announcement dated 27-Aug-2016 that the Board of Directors, at its meeting, have in-principle approved a proposal to merge Neuland Health Sciences Private Limited (Holding Company) and Neuland Pharma Research Private Limited (subsidiary of the Holding Company) with Neuland Laboratories Limited ( the Company ), subject to all necessary approvals.On basis of above the Company is required to clarify following:1. Name of the entity (ies) forming part of the amalgamation/merger, details in brief such as, size, turnover etc.;2. Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";3. Area of business of the entity (ies);4. Rationale for amalgamation/ merger;5. In case of cash consideration amount or otherwise share entitlement/exchange ratio; 6. Brief details of change in shareholding pattern (if any) of listed entity.The response of the Company is awaited.19 Aug · Analysts
13 Aug · Regulation 44(3) of SEBI (LODR), Reg., 2015
9 Aug · Analysts
8 Aug · Analysts
Jul 2016
20 Jul · Analysts
20 Jul · Analysts
1 Jul · Analysts
Jun 2016
21 Jun · Analysts
20 Jun · Analysts
16 Jun · Analysts
1 Jun · Analysts
1 Jun · Analysts
May 2016
31 May · Updates
12 May · Updates
Apr 2016
Mar 2016
16 Mar · Meeting
Feb 2016
Jan 2016
25 Jan · Updates